RTP Mobile Logo
A Conversation with the Investigators: Ovarian Cancer (Webinar Video Proceedings)
Released August 2021

Featuring perspectives from Drs Michael J Birrer, Kathleen Moore and Richard T Penson. Published August 12, 2021. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of ovarian cancer.


    • Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing platforms in ovarian cancer (OC), and use the results of these assessments to guide long-term treatment.
    • Consider the FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC harboring a deleterious or suspected deleterious BRCA germline or somatic mutation, and counsel appropriate individuals regarding personalized treatment recommendations.
    • Recognize the FDA approval of niraparib as maintenance therapy in the first-line setting for patients with advanced OC with or without BRCA mutations, and discern for which individuals treatment with this agent may be appropriate.
    • Evaluate available clinical trial data leading to the FDA approval of olaparib/bevacizumab as first-line maintenance therapy for patients with newly diagnosed OC responding after platinum-taxane chemotherapy with bevacizumab in order to determine the role of this novel strategy in clinical practice.
    • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to personalize care plans incorporating these agents.
    • Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize or ameliorate these side effects.
    • Appraise emerging data with and the potential clinical role of immune checkpoint inhibitors in combination with PARP inhibitors for patients with advanced OC.
    • Understand the scientific rationale for targeting folate receptor alpha in OC, and evaluate available data with mirvetuximab soravtansine alone or in combination with other anticancer therapies for patients with OC.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Michael J Birrer, MD, PhD
    Vice Chancellor, UAMS
    Director, Winthrop P Rockefeller Cancer Institute
    Director, Cancer Service Line
    University of Arkansas for Medical Sciences
    Little Rock, Arkansas

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: VBL Therapeutics.

    Kathleen Moore, MD
    The Virginia Kerley Cade Endowed Chair in Cancer Development
    Associate Director, Clinical Research
    Director, Oklahoma TSET Phase I Program
    Stephenson Cancer Center
    Associate Professor, Section of Gynecologic Oncology
    Director, Gynecologic Oncology Fellowship
    Department of Obstetrics and Gynecology
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Consulting Agreements: Aravive Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Sorrento Therapeutics, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Contracted Research: PTC Therapeutics, US Department of Defense.

    Richard T Penson, MD, MRCP
    Associate Professor of Medicine
    Harvard Medical School
    Clinical Director, Medical Gynecologic Oncology
    Massachusetts General Hospital
    Boston, Massachusetts

    Research Funding: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, VBL Therapeutics; Royalties: BMJ Publishing Group Ltd, Elsevier, Wolters Kluwer: Scientific Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Care4ward (Unpaid), Clovis Oncology, Curio Science (Vaniam Group), Eisai Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics, Nexus Group Global, Pieris Pharmaceuticals Inc, Roche Laboratories Inc, Sutro Biopharma, Syndax Pharmaceuticals Inc, Tesaro, A GSK Company, VBL Therapeutics.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GlaxoSmithKline, ImmunoGen Inc and Merck.

    Release date: August 2021
    Expiration date: August 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):